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Abstract 27 
 28 
Much attention has been given to insulin-like growth factor (Igf) pathways that regulate the balance 29 
of skeletal muscle protein synthesis and breakdown in response to a range of extrinsic and intrinsic 30 
signals. However, we have a less complete understanding of how the same signals modulate muscle 31 
mass upstream of such signalling, through a family of functionally-diverse Igf-binding proteins 32 
(Igfbps) that modify the availability of Igfs to the cell receptor Igf1r. We exposed cultured myotubes 33 
from Atlantic salmon (Salmo salar L.) to treatments recapturing three catabolic signals: inflammation 34 
(interleukin-1β), stress (dexamethasone) and fasting (amino acid deprivation), plus one anabolic 35 
signal: recovery of muscle mass post-fasting (supplementation of fasted myotubes with Igf-I and 36 
amino acids). The intended phenotype of treatments was confirmed by significant changes in 37 
myotube diameter and immunofluorescent staining of structural proteins. We quantified the mRNA-38 
level regulation of the full expressed Igf and Igfbp gene complement across a post-treatment time 39 
course, along with marker genes for muscle structural protein synthesis, as well as muscle 40 
breakdown, via the ubiquitin-proteasome and autophagy systems. Our results highlight complex, non-41 
overlapping responses of Igfbp family members to the different treatments, suggesting that the profile 42 
of expressed Igfbps is differentially regulated by distinct signals promoting similar muscle 43 
remodelling phenotypes. We also demonstrate divergent regulation of salmonid-specific gene 44 
duplicates of igfbp5b1 and igfbp5b2 under distinct catabolic and anabolic conditions. Overall, this 45 
study increases our understanding of the regulation of Igfbp genes in response to signals that promote 46 
remodelling of skeletal muscle. 47 
 48 
Keywords: Skeletal muscle, Myotubes, Cell culture, Insulin-like growth factor system; Igf binding 49 
proteins, Atlantic salmon, Dexamethasone, Interleukin-1β, amino acids. 50 
 51 
 52 
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1. Introduction  53 
 54 
Skeletal muscle growth involves a net accumulation of protein, with rates of protein synthesis 55 
exceeding that of degradation. One of the key systems regulating this balance is the insulin-like 56 
growth factor (Igf) - phosphoinositide 3 kinase (Pi3k) - Akt/protein kinase B (Akt) - mammalian 57 
target of rapamycin (mTor) pathway. The hormones Igf-I and Igf-II act as endocrine factors (Laron, 58 
1996; Wood et al. 2005), but are also released locally by tissues, including skeletal muscle 59 
(Schiaffino and Mammucari, 2011). Both Igfs are major anabolic factors in skeletal muscle, 60 
promoting protein synthesis, whilst inhibiting atrophy (Firth and Baxter 2002; Wood et al., 2005; 61 
Duan et al., 2010). The binding of Igf hormones to Igf1r, their primary cell-membrane receptor, 62 
initiates an intracellular phosphorylation cascade that activates Pi3k complexes and key downstream 63 
signalling molecules, most notably Akt (Hers et al., 2011), which in turn activates mTor/Raptor 64 
complexes – inducing an increase in protein translation via regulation of P70s6 kinases and Eif4ebp1 65 
family members (Wang and Proud, 2006). Regulation of Igfs in the extracellular environment (e.g. 66 
circulation and extracellular matrix) provides an important level of upstream control to these 67 
signalling events and is primarily governed by a family of functionally-diverse Igf binding proteins 68 
(Igfbp-1 to 6) present in all vertebrates, but particularly well-characterized in mammals. These Igfbps 69 
can either restrict Igf hormones from Igf1r or facilitate the accumulation of Igf on cell membranes in 70 
proximity to Igf1r (Firth and Baxter, 2002; Duan and Xu, 2005). Accordingly, the expression of 71 
different Igfbp subtypes allows for both inhibition and potentiation of Igf-signalling, which may 72 
allow appropriate muscle mass regulation according to signals favouring catabolism or anabolism. 73 
 74 
The ubiquitin-proteasome and autophagy-lysosome systems are major pathways leading to skeletal 75 
muscle protein degradation (Schiaffino et al., 2013). The ubiquitin-proteasome pathway is crucial for 76 
removal of sarcomeric proteins following muscle damage, in response to changes in muscle activity, 77 
or upon remodelling of muscle mass (Murton et al., 2008). Proteins to be degraded by the proteasome 78 
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are cross-linked by muscle-specific E3-ubiquitin ligases to ubiquitin (Schiaffino et al., 2013). The 79 
main recognized E3-ubiquitin ligases in skeletal muscle, employed widely as markers of muscle 80 
catabolism, are F-box only protein 32 (Fbxo32) (also called Atrogin-1 or Mafbx) and members of the 81 
muscle RING-finger (Murf) family (Glass 2005, Sacheck et al., 2007; Johnston et al. 2011; 82 
Macqueen et al. 2014). The autophagy-lysosome pathway also plays a key role in the turnover of 83 
cellular organelles during both normal and stressful conditions (Schiaffino et al., 2013). The Igf 84 
pathway negatively regulates both degradation pathways through activated Akt, which 85 
phosphorylates Foxo transcription factors, blocking their nuclear entry (Tzivion et al., 2011), causing 86 
downregulation of target genes including mafbx and murf1 (Glass, 2005), as well as key genes 87 
involved in lysosome formation and autophagy (Mammucari et al., 2007). The impact of external and 88 
endogenous signals driving skeletal muscle breakdown on these intracellular pathways is well 89 
characterized (Bonaldo and Sandri, 2013). For example, glucocorticoids such as the cortisol-analogue 90 
dexamethasone, increase the transcription of murf1, mafbx and autophagy genes, while inhibiting 91 
protein synthesis by blocking mTor function (Braun and Marks, 2015). In addition, cytokines, such as 92 
Tnfα and IL-1β increase the transcription of E3-ubiquitin ligases, including murf1 via Nfκβ pathways 93 
(Glass, 2005; Pooley et al., 2013). Finally, fasting stimulates protein degradation by repressing Akt 94 
activation, leading to FoxO-mediated transcriptional upregulation of both E3-ubiquitin ligases and 95 
macro-autophagy genes (e.g. Sandri et al., 2004; Southgate et al., 2007; Calnan and Brunet, 2008; 96 
Seiliez et al. 2010; Shimizu et al., 2011).   97 
 98 
Comparatively less is known about the role of Igfbps in skeletal muscle under such catabolic signals, 99 
particularly in teleost fish, where remodelling of muscle mass occurs routinely during the life cycle 100 
for reallocation of energy and amino acids between tissues (Johnston et al., 2011). For example, 101 
many teleosts undergo seasonal cycles of muscle wasting associated with migration and/or the 102 
mobilisation of amino acids to build gonadal tissue, followed by recovering after spawning (e.g. 103 
James and Johnston, 1998; Mommsen, 2004). Interestingly, in teleosts the Igfbp family is 104 
  
5 
 
characterized by additional gene duplicates (paralogues) of Igfbp1-6 retained from a whole genome 105 
duplication (WGD) event ancestral to all teleosts (i.e. Igfbp1a/b, 2a/b, 3a/b, 5a/b and 6a/b) (Ocampo 106 
Daza et al. 2011; Johnston et al. 2011; Macqueen et al. 2013). Additionally, in the salmonid family of 107 
teleosts (the focus of the current study), the Igfbp family consists of no less than nineteen unique 108 
genes (Macqueen et al. 2013; Lappin et al. 2016), owing to the retention of additional paralogues 109 
from a salmonid-specific WGD ~95 Ma (Macqueen and Johnston, 2014; Lien et al. 2016). This event 110 
has also expanded other components of the IGF system, including Igf1r (Alzaid et al. 2016a) and Igf-111 
II in some species (Lappin et al. 2016). Recent work on salmonid Igfbps in skeletal muscle has 112 
included studies of in vitro regulation during myogenesis under anabolic and catabolic signals 113 
(Gabillard et al. 2006; Bower and Johnston, 2010; Pooley et al. 2013) and in vivo regulation in 114 
response to fasting (e.g. Bower et al., 2008), temperature (Hevrøy et al., 2013) and sex steroids 115 
(Cleveland and Weber, 2015). Moreover, the salmonid Igfbp subtypes igfbp1a1 and igfbp6a2 have 116 
roles linking salmonid growth to conserved cytokine pathways regulating inflammatory responses 117 
(Alzaid et al. 2016b), with relevance to understanding muscle remodelling for energy reallocation 118 
(Pooley et al. 2013). In contrast, the regulation of Igfbps by dexamethasone (or other glucocorticoids) 119 
in fish skeletal muscle remains unstudied. 120 
 121 
The objective of this study was to improve our understanding of how the Igfbp gene family is 122 
regulated by a range of physiological stimuli known to induce remodelling of skeletal muscle mass. 123 
We quantified the transcriptional responses of the complete repertoire of expressed Igfbps in primary 124 
differentiated fast-twitch skeletal muscle cultures from Atlantic salmon (Salmo salar L.) using four 125 
experimental models that induced a catabolic or anabolic status, via pathways regulated by 126 
dexamethasone, proinflammatory cytokines, amino acids and Igf-I. Our results show distinct stimuli 127 
result in divergent and complex expression responses of Igfbp family member genes during muscle 128 
remodelling, including evolutionary divergence of salmonid-specific gene duplicates. 129 
 130 
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2. Materials and Methods 131 
 132 
2.1. Ethics statement 133 
The University of St Andrews Animal Ethics and Welfare Committee approved all the experimental 134 
procedures described. Fish were sacrificed by a blow to the head before sectioning of the spinal cord 135 
(Schedule-1 killing protocol; Animals Act 1986; Home Office Code of Practice. HMSO: London 136 
January 1997). 137 
 138 
2.2. Myotube cell culture  139 
Atlantic salmon (Salmo salar L.) were maintained at the Scottish Oceans Institute (University of St 140 
Andrews) in 200L fibreglass freshwater tanks at 10oC with a 16:8 light/dark photoperiod. Myogenic 141 
progenitor cells (MPCs) were extracted from 10-14g Atlantic salmon parr (immature fish of unknown 142 
sex) and cell culture performed as previously described (Garcia de la serrana and Johnston, 2013). 143 
Briefly, epaxial fast skeletal muscle was extracted (total 40g of muscle, n=10 to 14 randomly-144 
sampled fish per culture), mechanically dissected and enzymatically digested with trypsin and 145 
collagenase, then washed and filtered several times until MPCs were obtained. Cells were cultured in 146 
laminin-coated well plates and maintained with Dulbecco’s modified eagle’s media (DMEM; Sigma, 147 
Dorset, UK), 9mM NaHCO3 (pH 7.4) (Sigma), 20mM HEPES (Sigma), 10% (v/v) foetal bovine 148 
serum (Sigma) and an antibiotic/antimycotic cocktail (Sigma) at 18oC for 10 days until fully 149 
differentiated myotubes were formed.  150 
 151 
2.3. Experimental treatments 152 
Catabolic and anabolic treatments were performed in day-10 differentiated Atlantic salmon myotubes 153 
in independent cultures (n=5). Catabolism was induced by addition of 1µM of dexamethasone 154 
(+DEX treatment) (Sigma), 3ng/ml of recombinant interleukin-1β (produced following Hong et al. 155 
2001) (+IL-1β treatment) or using an amino acid free cell culture media (-AA treatment). In order to 156 
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establish conditions that induced myotube atrophy without affecting cell viability, dexamethasone 157 
and IL-1β concentrations were obtained from the literature (Menconi et al., 2008; Pooley et al., 2013) 158 
and a pilot study was carried out to test different concentrations (data not shown). Myotubes were 159 
incubated in bovine serum free media for two hours to reduce gene expression to basal levels before 160 
+DEX and +IL-1β treatments. Total RNA was extracted (section 2.4) at 0, 1, 3, 6, 24 and 48 hours 161 
post-treatment. For the AA- treatment, a modified culture media with no amino acids was used 162 
(Garcia de la serrana and Johnston, 2013) and total RNA extracted at 0, 1, 3, 6, 24 and 48 hours. The 163 
anabolic treatment (+AA+Igf-I) involved a restitution of amino acids in the -AA cell culture media 164 
(at 48 hours) combined with 100nM of recombinant Atlantic salmon Igf-I (GROPEP, Australia). 165 
Total RNA from the +AA+Igf-I treatment was collected 3, 6 and 24 hours after the +AA+Igf-I 166 
treatment. In all cases, myotubes with normal free-serum DMEM media were maintained in parallel 167 
as controls (-DEX, -IL-1β, +AA and +AA-Igf-I) for each of the conditions tested and sampled at the 168 
same time as treated cells.  169 
 170 
2.4. RNA extraction and cDNA synthesis 171 
Total RNA was extracted from two wells per time-point, per treatment and culture using an RNeasy 172 
extraction kit (Qiagen, Manchester, UK), following the manufacturers protocol. RNA concentrations, 173 
230/260 and 280/260 ratios were determined using a Nanodrop 1000 spectrophotometer (Nanodrop, 174 
ThermoFisher Scientific). RNA with respective 260/280 and 260/280 ratios over 1.8 and 2 was used 175 
for cDNA synthesis. 250ng of RNA was reverse transcribed for each sample using a Quantitech kit 176 
(Qiagen), following the manufacturers guidelines, including a step to remove residual genomic DNA.  177 
Control samples with RNA but no reverse transcriptase (-RT) were included. The 1:1 first-strand 178 
cDNA was diluted 40x and stored at -20oC until use in quantitative PCR (qPCR) (section 2.6). A pool 179 
of all first-strand cDNAs generated was used as an interplate calibrator (IPC) for qPCR analysis 180 
(section 2.6). 181 
 182 
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2.5. Primer design  183 
Primers used for amplification of the complete salmonid Igfbp family (19 genes), as well as mafbx, 184 
murf1, igf2, myl1, tnni1 and the housekeeping genes hprt1, rpl4, rps13, rps29 have been described 185 
elsewhere (Bower et al., 2008; Macqueen et al., 2010; 2013; Alzaid et al., 2016b). New primers for 186 
paralogues encoding autophagy related 4b cysteine protease (atg4b) genes were designed for use in 187 
this study. First, BLASTn searches of the Atlantic salmon genome (via Salmobase.org) revealed two 188 
atg4b paralogues on Chr. 10 and 16 (respective NCBI accession numbers: NM_001139775 and 189 
XM_014149865), embedded within a large collinear duplicated block retained from the salmonid 190 
specific WGD (Lien et al. 2016). These salmonid-specific paralogues were named atg4b1 (Chr. 10) 191 
and atg4b2 (Chr. 16). Primers designed to be specific to each gene are as follows (underlined bases 192 
distinguish the two paralogues):  atg4b1 - Fwd: 5’ – GACTGGAGATGGGTGAGGAGC -  3’ 193 
(melting temperature, Tm = 61 oC); Rev: 5’ – CCGTTAGGCTCTGGCATACC – 3’ (Tm = 60 oC) 194 
(product size = 382 bp) and atg4b2 - Fwd: 5’ – GAGACTGGAGATGGGTGAGAGG -  3’ (Tm = 60 195 
oC); Rev: 5’ – GGCAGCCGTTATGCGTCG – 3’ (Tm = 63 oC) (product size = 340 bp). For both 196 
atg4b paralogues, the primers in a pair were separated by at least three exons in the gene. 197 
 198 
2.6. qPCR analysis 199 
All qPCR experiments were compliant with MIQE guidelines (Bustin et al., 2009). Each reaction 200 
contained 6µl of 1:40-diluted cDNA, 7.5µl of 2x Brilliant III SYBRGreen master mix (Agilent, 201 
Cheshire, UK) and 1.5µl of sense/antisense 500nM primer mix. Amplifications were performed in 202 
duplicate in a Stratagene Mx3005P thermocycler (Agilent) with the following conditions: 3 min at 203 
95oC, followed by 40 cycles of 20s at 95oC then 20s at 65oC, followed by a dissociation analysis 204 
(60°C to 95°C thermal gradient; single product observed in all final assays). No-template (-NT; water 205 
in place of cDNA) and –RT controls were included in duplicate for each qPCR assay. The IPC cDNA 206 
sample was included in quadruplicate using the same primer pair (rps29) on every qPCR plate. 207 
Threshold crossing/quantification cycles (Cq) were calculated from baseline-corrected data with the 208 
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threshold fixed across plates at 0.25. Cq-36 was considered the cut-off of no expression (note: Cq 209 
was always >40 for -RT and -NTC controls). LinRegPCRv.11 software was used to calculate primer 210 
efficiency following the author’s recommendations (Ruijter et al. 2009). Cq values were exported to 211 
Genex v.4.4.2 (MultiD Analyses AB) and corrected for differences in efficiency before any plate-to-212 
plate variation was corrected using the IPC Cq values.  213 
 214 
An assessment of reference gene suitability was performed using Normfinder (Andersen et al. 2004) 215 
within Genex. Normfinder was used to consider variance in expression of the four reference genes 216 
both globally and across the post-treatment time courses (considering controls vs. treatments). This 217 
was done with pooled cDNAs for each biological replicate (separate pools of replicates for +DEX, -218 
DEX, +IL-1β, -IL-1β, –AA +AA, +AA+Igf1 and +AA-Igf1) and sampling points (0, 1, 3, 6, 24, and 219 
48h) (n=42 sample points) providing a study-wide overview of reference gene stability. We also 220 
performed a Normfinder analysis of all four reference genes considering the Dexamethasone study 221 
with full biological replication (n=60 samples; -DEX and +DEX across 6 timepoints). Each of the 222 
four reference genes were expressed very stably in the pooled samples, both globally and with respect 223 
to treatment and time-point (Normfinder SD values: 0.17-0.22). The Dexamethasone data revealed 224 
that rps29, rps13 and rpl4 were stably expressed (global Normfinder SD values of 0.06-0.20), with 225 
rps29 being the most stable. Importantly, the accumulative SD of references genes, which is 226 
indicative of the appropriate number of reference genes to employ for normalization, was not lowered 227 
(improved) by considering additional reference genes to rps29. Thus, using Genex, we normalized 228 
the efficiency-corrected Cq values for all experimental genes measured across the study to the 229 
relevant rps29 Cq values, before placing the expression data on a relative scale quantitatively 230 
comparable across all experimental genes.  231 
 232 
2.7. Muscle fibre diameter and immunofluorescence measurements 233 
 234 
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To measure myotube diameter and perform immunofluorescence detection, MPCs were grown on 235 
borosilicate coverslips coated with poly-L-lysine and laminin until fusion. Diameter was measured in 236 
10-day differentiated myotubes from all tested treatments. Culture media was removed 24 and 48 237 
hours after myotubes were incubated with the different treatments and control media, and washed 238 
twice with PBS. Duplicate coverslips for each time-point (24h and 48h; treatment and controls) were 239 
fixed in 4% (m/v) paraformaldehyde (Sigma) in PBS (pH 7.4) for 20 minutes at room temperature, 240 
washed twice with PBS and kept at 4oC in a solution of PBS 0.01% NaN3 (Sigma) until further 241 
analysis. Photographs were taken at random for each time-point, treatment and culture (n=4 in each 242 
case), using a bright field microscope at 20x magnification. ImageJ software (National Institute of 243 
Health, Maryland, USA) was used to determine myotube diameter by measuring the thickness at 5 244 
different locations along the myotube. Measurements were obtained from between 15 and 30 245 
randomly selected myotubes. Final myotube diameter was taken as the average of the 5 246 
measurements (100 to 150 myotubes per treatment/relevant controls). 247 
 248 
Immunofluorescence against actin and desmin filaments was visualised based on a protocol outlined 249 
previously (Garcia de la serrana and Johnston, 2013). Fixed myotubes were washed twice in PBS and 250 
incubated with 0.5% Triton X-100 (v/v) (Sigma) PBS for 5 min. Non-specific binding sites were 251 
blocked with 5% (v/v) normal goat serum (Sigma), 1.5% (w/v) Bovine serum albumin (Sigma), 0.1% 252 
(v/v) Triton X-100 (v/v) PBS for 1 hour at room temperature. Actin filaments were visualized by 253 
incubation with Phalloidin-ATTO 488 antibody (Sigma) for 2 hours at room temperature at 1:100 254 
dilution in 1.5% BSA (w/v) 0.1% Triton X-100 (v/v) PBS and counterstained with DAPI 1:500 in 255 
sterile water for 5 minutes. Desmin filaments were detected by incubating the cells with an anti-256 
Desmin antibody (SIGMA) 1:20 (v/v) in 1.5% BSA 0.1% Triton X-100 PBS overnight at 4oC. To 257 
visualize the filaments, myotubes were incubated with anti-rabbit Alexa Fluor 546 (ThermoFisher) 258 
secondary antibody at 1:400 (v/v) dilution in 1.5% BSA 0.1% Triton X-100 for 2 hours at room 259 
temperature and counterstained with DAPI 1:500 in sterile water for 5 minutes. Myotubes were 260 
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visualized and digitally imaged using a Leica TCS SP2 confocal microscope (Leica Microsystems) at 261 
20x magnification.   262 
 263 
2.8. Statistical analysis  264 
All statistical analyses were performed using RStudio (RStudio Team 2015). Pairwise comparisons of 265 
myotube diameter between treatments and controls were done using a Student’s t-test. For analysis of 266 
the gene expression data, a general linear model approach was used with treatment and time-point as 267 
fixed factors. The Shapiro-Wilk test was used to scrutinize the assumption of normality in the linear 268 
model residuals. Expression data that failed to follow a normal distribution was transformed using a 269 
Box-Cox power transformation and tested again. Data that did not follow normality after Box-Cox 270 
power transformation was analysed using a Kruskal-Wallis non-parametric test.  271 
 272 
3. Results  273 
 274 
3.1. Effect of catabolic and anabolic treatments on myotube diameter 275 
The effect of the different treatments on salmon myotube morphology and cytoskeleton arrangement 276 
was assessed 24 and 48 hours after treatment using bright field microscopy and immunofluorescence 277 
against actin and desmin filaments (Figure 1A; Supplementary File 1). After 48 hours treatment, each 278 
tested catabolic treatment caused a reduction in the number of differentiated myotubes and an 279 
increase in the presence of single cells, evidenced both by bright microscopy (Figure 1A, i-k vs. 280 
control data in a-c) and desmin immunofluorescence (Figure 1A, m-o vs. control data in e-g). 281 
Considering that we used differentiated myotubes as the starting point for each treatment, a reduction 282 
in the number of myotubes, coupled with an increase in the number of single cells, might be 283 
explained by a dramatic reduction in the integrity of the myotube cytoskeleton. In other words, the 284 
apparent single cells may actually remain part of myotubes where the cytoskeleton has undergone 285 
extensive atrophy. Bright-field microscopy (Figure 1A, d, i) and desmin immunofluorescence (Figure 286 
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1A, h, p) showed that the addition of amino acids and Igf-I (+AA+Igf) to myotubes under amino acid 287 
deprivation for 48h (-AA-48h) (Figure 1A, d, h) induced myotube hypertrophy (Figure 1A, i, p). 288 
 289 
To quantify the accompanying phenotypic changes in myotubes, we compared myotube diameters for 290 
all treatments against controls. +DEX and -AA treatments reduced myotube diameter by ~30-40% at 291 
24 and 48 hours compared to controls (all P < 0.001) (Figure 1B and C). The +IL-1β treatment 292 
reduced myotube diameter by ~10% at 24 hours (P = 0.055) and by ~30% at 48 hours (P < 0.001) 293 
(Figure 1D). When amino acids and Igf-I were added to the -AA culture (-48h time-point), myotube 294 
diameter increased to pre-treatment values in 24h (P < 0.001) (Figure 1B). These data confirm that 295 
the treatments induced the intended myotube phenotypic changes, which provides a robust platform 296 
to interpret gene expression responses measured in the same experimental samples (section 3.2). 297 
 298 
3.2. Gene expression responses to catabolic and anabolic stimuli 299 
Genes encoding all 19 Igfbps were quantified using qPCR in Atlantic salmon myotubes, but 10 were 300 
not detected, namely igfbp1a2, igfbp1b1, igfbp2b1, igfbp2b2, igfbp3a2, igfbp3b1, igfbp3b2, igfbp6a2 301 
and igfbp6b1. Given that the relevant primers have been verified in past studies where expression of 302 
all 19 genes was reported (e.g. Macqueen et al. 2013; Alzaid et al. 2016b), we concluded that these 303 
igfbp genes were not expressed in salmon myotubes. In parallel, genes encoding two E3-ubiquitin 304 
ligases (mafbx, murf1), two fast-twitch skeletal muscle sarcomere components (myosin light chain, 305 
myl1 and troponin I, tnni1), the Igf-II hormone (igf2) and two autophagy related genes (atg4b1, 306 
atg4b2) were also analysed. 307 
 308 
3.2.1. +DEX treatment 309 
10 of the 16 tested genes were significantly regulated by the +DEX treatment compared to controls 310 
(P <0.05 for treatment effect), including those encoding 6 of the 10 expressed Igfbp family members, 311 
both tested E3 Ubiquitin ligases, one of the atg4b paralogues and igf2 (Table 1). In addition, 4 of the 312 
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10 genes with a significant treatment effect showed a significant treatment*time-point interaction, 313 
indicating marked differences in the response to dexamethasone at different time-points (Table 1). 314 
Among these were two genes encoding Igfbp6 family members (igfbp6a1 and igfbp6b2), which 315 
showed reciprocal responses across the treatment time course. Specifically, comparing +DEX to 316 
control cultures, igfbp6a1 was most highly downregulated, while igfbp6b2 was most highly 317 
upregulated at later time-points (24 to 48 hours) of the culture (Figure 2A, B), where atrophy was 318 
evident (Figure 1B-D). A similar pattern was observed for two Igfbp5 family members, with igfbp5a 319 
being downregulated at 24 to 48 hours post treatment and igfbp5b1 being strongly induced from 6 320 
hours post-treatment (Figure 2C, D). The other two Igfbp family members that responded 321 
significantly to the +DEX treatment (igfbp4 and igfbp2a) showed a less pronounced trend in the 322 
nature and magnitude of response across time-points (Figure 2E, F). The two E3 Ubiquitin ligase 323 
genes showed highly distinct responses to the +DEX treatment (Figure 2G, H). Specifically, mafbx 324 
was induced from early stages of the culture (before notable changes in myotube diameter were 325 
observed), through to 24 hours, when atrophy was first observed (Figure 1C) but returned to control 326 
levels by 48 hours (Figure 2G). Conversely, murf1 was induced relative to control levels at 24 and 48 327 
hours sampling points (Figure 2H). In addition, both igf2 and atgb42 were markedly induced at 24 328 
and 48 hours post +DEX treatment (Figure 2I, H).  329 
 330 
Therefore, the most pronounced changes in gene expression responses to dexamethasone occurred at 331 
stages of the culture (post-6 hours), when myotube remodelling was evident. 332 
 333 
3.2.3. +IL-1β treatment 334 
Despite our observation that myotube diameter decreased significantly in response to the +IL-1β 335 
treatment by 48 hours (Figure 1D), only 2 of the 16 tested genes were significantly regulated during 336 
this remodelling of myotube phenotype (Table 2; Figure 3). This included igfbp1a1, which was 337 
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downregulated at 3, 6 and 48 hours post-treatment, but not other time-points (Table 2; Figure 3A). In 338 
contrast, murf1 was increased in response to controls, most notably at 48 hours (Figure 3B).  339 
 340 
3.2.4. -AA treatment  341 
The -AA treatment was accompanied by significant responses in only 3 of the 16 tested genes (Table 342 
3; Figure 4), despite clear evidence of myotube atrophy (Figure 1B). Two of the genes significantly 343 
regulated by the –AA treatment were the same Igfbp6 family members that were strongly affected by 344 
dexamethasone (section 3.2.2). Specifically, both igfbp6a1 and igfbp6b2 were downregulated during 345 
the –AA treatment time course relative to controls (Table 3), with igfbp6a1 being particularly 346 
strongly affected from 6 hours post treatment (Figure 4A, B). The other gene significantly affected by 347 
the –AA treatment, mafbx, was downregulated at many sampled time-points (Table 3; Figure 4C). 348 
 349 
3.2.5. +AA+Igf-I treatment 350 
The +AA+Igf-I treatment, which was accompanied by a significant recovery of myotube diameter 351 
(i.e. anabolic state) (Figure 1B), led to significant responses in 8 of the 16 tested genes, including 4 352 
encoding Igfbp family members, mafbx, igf2 and both paralogues of atg4b (Table 4; Figure 5). 353 
Among the significantly responsive Igfbp genes, three were increased, either transiently (igfbp6b2, 354 
Figure 5A), or consistently across multiple timepoints (igfbp5b1 and igfbp4, Figure 5B, C). 355 
Conversely, igfbp1a1 was downregulated at all timepoints post +AA+Igf-I treatment (Figure 5D). 356 
Finally, while mafbx and both atgb4b duplicates were downregulated by the +AA+Igf-I treatment at 357 
multiple sampled timepoints, igf2 was upregulated (Figure 5E-H). 358 
 359 
4. Discussion 360 
 361 
Here we addressed the regulation of Igfbp gene expression in skeletal muscle remodelling, which is 362 
poorly understood in teleost fish. Our study is the first to systematically document the regulation of 363 
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the complete Igfbp gene family under several distinct catabolic and anabolic conditions, done with 364 
full knowledge of gene paralogues retained from both the teleost and salmonid-specific WGD events, 365 
which if ignored can limit physiological interpretations of gene expression (Johnston et al. 2011). 366 
Though all three tested catabolic signals (i.e. dexamethasone, IL-1β and amino acid deprivation) 367 
induced atrophy of differentiated myotubes (Figure 1), the responses of different Igfbp genes, as well 368 
as other relevant marker genes, showed remarkable variability across the tested experimental models 369 
(Tables 1-3; Figures 2-5). This was true not only for the number of genes showing a significant 370 
response (i.e. from only 2 genes responding to IL-1β, up to 10 to dexamethasone), but also the 371 
particular Igfbp genes that responded to different stimuli. This points to complex and context-372 
dependent transcriptional regulation of Igfbp gene expression via several unique pathways that 373 
promote muscle remodelling. 374 
 375 
Dexamethasone-induced atrophy of salmon myotubes (Figure 1) was accompanied by a complex 376 
expression response of different Igfbp genes (Figure 2). The catabolic state of the myotubes was also 377 
evidenced by upregulation of mafbx, murf1 and atg4b1 (Table 1), suggesting activation of the 378 
proteasome and autophagy systems. However, we also observed Igf system expression responses that 379 
are difficult to reconcile with a purely catabolic state, particularly the upregulation of igf2, igfbp4 and 380 
igfbp5b1 (Table 1). While past work has showed that igf2 is likewise induced by dexamethasone in 381 
salmonid hepatocytes (Pierce et al. 2010), its protein product, along with Igfbp5, are established pro-382 
myogenic factors in mammals with key roles in differentiation (e.g. Stewart et al. 1996; Ren et al. 383 
2008). Similarly, igfbp4 has pro-growth functions in salmonid muscle (Johnston et al. 2011; e.g. 384 
Bower et al. 2008; Macqueen et al. 2011). Despite this, past in vitro studies have also shown that both 385 
igf2 and igfbp5b1 are much more highly expressed in mononuclear MPCs compared to differentiated 386 
myotubes, suggesting roles in early phases of myogenesis, such as MPC proliferation (Bower and 387 
Johnston, 2010). Additionally, dexamethasone, despite being a potent inducer of atrophy (e.g. Braun 388 
and Marks, 2015) has been shown to activate IGF-signalling pathways promoting early phases of 389 
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myogenesis (Giorgino and Smith, 1995). Thus, some observed Igfbp system expression responses 390 
might result from stimulation of such IGF-signalling pathways, despite the overall catabolic status of 391 
salmon myotubes. 392 
 393 
The reciprocal responses of two functionally-related Igfbp5 teleost family members to 394 
dexamethasone, with igfbp5a downregulated and igfbp5b1 upregulated (Figure 2C, D) is also notable, 395 
as past reports have suggested that mammalian Igfbp5, while being essential for mammalian muscle 396 
differentiation (Ren et al. 2008), can also inhibit muscle differentiation under some physiological 397 
contexts (Ewton et al. 1998). One explanation for our data is that such divergent roles of Igfbp5 have 398 
been partitioned to the individual teleost paralogues during evolution. Interestingly, among the other 399 
Igfbp genes that responded to dexamethasone, only igfbp6a1 and igfbp6b2 were significantly 400 
regulated under any other tested atrophy stimulus, specifically in response to amino acid deprivation 401 
(discussed further below). Even then, while igfbp6a1 was downregulated under both conditions, 402 
consistent with a common underlying role, igfbp6b2 was upregulated by dexamethasone, but 403 
downregulated by amino acid deprivation. Moreover, during recovery myotube growth (induced by 404 
addition of amino acids and Igf-I to cell cultures previously deprived of amino acids), igfbp6b2 was 405 
increased (i.e. as observed for dexamethasone) despite the myotube showing an anabolic rather than 406 
catabolic status. The role of Igfbp6 in teleost muscle remodelling is clearly complex (discussed 407 
below), both in response to dexamethasone and other signals, and warrants further study. 408 
 409 
In contrast to dexamethasone, IL-1β-induced myotube atrophy was not accompanied by marked 410 
changes in the expression of Igfbp family members and other tested genes (Table 2). This contrasts 411 
two past studies where a much higher dose of IL-1β was administered to Atlantic salmon myocytes 412 
previously cultured for 4 days (25 ng/ml dose; Pooley et al. 2013) or 7 days (50-200 ng/ml dose; 413 
Heidari et al. 2016) and several Igfbp genes were strongly affected (Pooley et al. 2013), including the 414 
robust induction of an undefined Igfbp6 family member (Pooley et al. 2013; Heidari et al. 2016). 415 
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However, as we cultured myocytes for 10 days before IL-1β treatment, our study represents a more 416 
advanced state of differentiation (Bower et al., 2010; Bower and Johnston, 2010; Garcia de la serrana 417 
et al., 2013). Thus, the discrepancies between our study and these past investigations presumably 418 
reflect differences in both the concentrations of IL-1β used, but potentially also the ontogeny of the 419 
cell culture. Interestingly, in another study, a strong upregulation of Igfbp6a2 was observed in 420 
rainbow trout (Oncorhynchus mykiss) following in vivo bacterial challenge at the fry stage, a response 421 
that was strikingly correlated to that of master genes regulated by proinflammatory cytokine 422 
pathways, including IL-1β (Alzaid et al. 2016b). However, in that past study, the tissues responsible 423 
for igfbp6a2 upregulation were not determined and whether skeletal muscle was involved remains 424 
unknown. In our study, igfbp1a2 (the single Igfbp1 family member expressed in myotubes) was 425 
slightly downregulated in response to IL-1β (Table 2). However, its salmonid-specific paralogue 426 
igfbp1a2 is robustly induced during bacterial infection, which is presumed to restrict Igf hormones in 427 
the circulation (Alzaid et al. 2016b), consistent with past studies showing that salmonid Igfbp1 family 428 
members are upregulated in circulation in response to catabolic physiological states (e.g. Kawaguchi 429 
et al. 2015). Thus, the downregulation of igfbp1a2 in atrophic salmon myotubes points to differences 430 
in the local and systematic roles of Igfbp1 family members of teleosts. In addition, past work 431 
documented a minor induction of mafbx in response to IL-1β in salmon myocytes (Pooley et al. 432 
2013), which, again was not detected in our study. However, murf1, another E3-Ubiquitin ligase, was 433 
upregulated (Table 2). Past reports in mammal myotubes has shown that both E3-Ubiquitin ligases 434 
are stimulated by IL-1β through NF-κB signalling pathways (e.g. Li et al. 2009).  435 
 436 
As for IL-1β, we observed a paucity of transcriptional responses in atrophic salmon myotubes 437 
deprived of amino acids (Table 3), similar to previous reports (Bower and Johnston, 2010). However, 438 
a separate past study showed that the E3-Ubiquitin ligase mafbx was robustly induced by the same 439 
treatment (Bower et al. 2010), which was not observed in our data. The only other genes that 440 
responded to amino acid deprivation were igfbp6a1 and igfbp6b2 (Figure 4A, B), which were each 441 
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strongly decreased, which contrasts with the fact that Igfbp6 is a negative regulator of Igf signalling, 442 
particularly through Igf-II, which in mammals binds Igfbp6 with much higher affinity than Igf-I 443 
(Bach, 2016). Thus, we suggest that the complex expression responses of different Igfbp6 family 444 
members observed in our study, with both positive and negative regulation in myotubes under 445 
verified catabolic states is likely related to the plethora of characterized cellular actions for Igfbp6 446 
that are IGF-independent (Bach, 2016).  447 
 448 
A stronger expression response for the tested genes was observed during myotube recovery growth 449 
induced by amino acids and Igf-I treatment in previously-fasted salmon myotubes, including 450 
downregulation of mafbx and both atg4b paralogues, suggesting repression of the proteasome and 451 
autophagy pathways. A concurrent upregulation of several Igf system genes that are considered pro-452 
myogenic, including igf2, igfbp5b1 and igfbp4, was also consistent with the observed anabolic state 453 
of myotubes and highly congruent with past data using a similar experimental model (Bower et al., 454 
2008). However, the strong episodic upregulation of igfbp6b2 in response to the +AA+Igf-I treatment 455 
(Figure 6A) has not been observed before and will warrant further investigation, especially in light of 456 
the diverse expression responses of Igfbp6 family members observed in our broader study. 457 
 458 
A final discussion point is the differential expression of salmonid-specific paralogues in our study. 459 
Past work has emphasized the enormous extent of transcriptional divergence that has evolved among 460 
such duplicates since the salmonid WGD ~95 Ma, which has been previously demonstrated both at 461 
the genome-wide level (across tissues; Lien et al. 2016) and for important gene families in response 462 
to various physiological stimuli (e.g. Macqueen et al. 2010; Garcia de la Serrana et al. 2013; Alzaid et 463 
al. 2016b). For the Igfbp family, the only such gene duplicates expressed in salmon myotubes were 464 
igfbp5b1 and igfbp5b2. In a recent past study, these two genes were shown to have similar regulation 465 
during the early development of rainbow trout (Alzaid et al. 2016b). Here, we observed divergent 466 
responses of igfbp5b1 and igfbp5b2 to dexamethasone (Table 1) and the +AA+Igf-1 treatment (Table 467 
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4), which likely reflects evolutionary divergence in regulatory sequences controlling transcription. 468 
Again, such findings emphasize the importance of identifying and distinguishing gene duplicates in 469 
investigations of salmonid physiology. 470 
 471 
5. Conclusion 472 
This study improves our understanding about how a range of stimuli induce catabolic and anabolic 473 
status in salmonid myotubes and highlights great evident complexity in the roles played by different 474 
Igfbp family members in the control of salmonid skeletal muscle mass.  475 
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Figure legends 697 
Figure 1. Changes in Atlantic salmon myotubes in response to catabolic and anabolic treatments. (A) 698 
Bright field images (a-d, i-l) or immunofluorescence against desmin filaments (e-h, m-p) is shown in 699 
response to the +IL-1β (a, e, i, m), -AA (b, f, j, n), +DEX (c, g, k, o) and +AA+Igf-I (d, h, l, p) 700 
treatments after 48 hours. All pictures were taken at 20x magnification. The scale bars represent 701 
150µm. (B) Changes in myotube diameter in response to -AA treatment vs. controls (+AA) and 702 
+AA+IGF treatment. (C) Changes in myotube diameter in response to the +DEX treatment vs. 703 
controls (-DEX). (D) Changes in myotube diameter in response to +IL-1β treatment vs. controls (-IL-704 
1β). Each box and whisker plot shows measurements from 100 to 150 myotubes. Significant 705 
differences (P < 0.05) between controls and treatments are indicated at 24 hours (*), 48 hours (#) and 706 
between -AA vs. +AA+IGF (+). The symbols ‘***’, ‘###’ and ‘+++’ highlight differences at P < 707 
0.001. 708 
 709 
Figure 2. Significant mRNA-level expression responses to +DEX treatment for igfbp6a1 (A), 710 
igfbp6b2 (B), igfbp5a (C), igfbp5b1 (D), igfbp4 (E), igfbp2a (F), mafbx (G), murf1 (H), igf2 (I) and 711 
atg4b2 (J) at 0, 1, 3, 6, 24 and 48 hours post-treatment showed as arbitrary units for controls (full bar 712 
chart) and treated (empty bar chart) myotubes. Values for bar chart are mean + SD (n=5). Complete 713 
details of gene expression responses for all genes tested in the study is provided in Table 1. 714 
 715 
Figure 3. Significant mRNA-level expression responses to +IL-1β treatment for igfbp1a1 (A) and 716 
murf1 (B). All other details are as given in the Figure 2 legend. Complete details of gene expression 717 
responses for all genes tested in the study is provided in Table 2. 718 
 719 
Figure 4. Significant mRNA-level expression responses to –AA treatment for igfbp6a1 (A), igfbp6b2 720 
(B) and mafbx (C). All other details are as given in the Figure 2 legend. Complete details of gene 721 
expression responses for all genes tested in the study is provided in Table 3. 722 
  
29 
 
 723 
Figure 5. Significant mRNA-level expression responses to +AA+Igf-I treatment for igfbp6b2 (A), 724 
igfbp5b1 (B), igfbp4 (C), igfbp1a1 (D), mafbx (E), igf2 (F), atg4b1 (G) and atg4b2 (H) at 3, 6 and 24 725 
hours post-treatment. All other details are as given in the Figure 2 legend. Complete details of gene 726 
expression responses for all genes tested in the study is provided in Table 4. 727 
 728 
Supplementary File 1. Myotube morphology in response to catabolic and anabolic treatments. 729 
Bright field microscopy or immunofluorescence against desmin (red) and actin (green) filaments for 730 
myotubes under different experimental conditions. All pictures were taken using x20 magnification. 731 
The scale bar for each picture represents 150µm. 732 
 733 
  
0.0
0.5
1.0
1.5
2.0
2.5
m
R
N
A 
ex
pr
es
si
on
 
ig#p6b2(
0.0
0.5
1.0
1.5
2.0
m
R
N
A 
ex
pr
es
si
on
 
ig#p5b1(
0
5
10
15
20
25
m
R
N
A 
ex
pr
es
si
on
 
ig#p4&
0
20
40
60
80
m
R
N
A 
ex
pr
es
si
on
 
ig#p1a1'
0
5
10
15
m
R
N
A 
ex
pr
es
si
on
 
ma#x%
0
5
10
15
20
m
R
N
A 
ex
pr
es
si
on
 
igf2%
0
10
20
30
40
m
R
N
A 
ex
pr
es
si
on
 
atg4b1'
0
20
40
60
m
R
N
A 
ex
pr
es
si
on
 
atg4b2'
A	
C	
E	
G	
B	
D	
F	
H	
3h	 24h	-AA_48h	 1h	 3h	 24h	-AA_48h	 1h	
ig#p6b2	 ig#p5b1	
ig#p4	 ig p1a1	
ma#x	 igf2	
atg4b1	 atg4b2	
  
0.0
0.5
1.0
1.5
2.0
m
R
N
A 
ex
pr
es
si
on
 
ig#p6a1(
0.0
0.1
0.2
0.3
0.4
m
R
N
A 
ex
pr
es
si
on
 
ig#p6b2(
0
5
10
15
m
R
N
A 
ex
pr
es
si
on
 
ma#x%
A	
B	
C	
0h	 3h	 6h	 24h	 48h	1h	
ig#p6a1	
i p6b2	
	
  
0
20
40
60
m
R
N
A 
ex
pr
es
si
on
 
ig#p1a1'
0
2
4
6
8
10
m
R
N
A 
ex
pr
es
si
on
 
murf1&
A
B	
0h	 3h	 6h	 24h	 48h	1h	
ig 	
murf1	
  
0.0
0.5
1.0
1.5
2.0
m
R
N
A 
ex
pr
es
si
on
 
ig#p6a1(
0.0
0.1
0.2
0.3
0.4
0.5
m
R
N
A 
ex
pr
es
si
on
 
ig#p6b2(
0.0
0.5
1.0
1.5
m
R
N
A 
ex
pr
es
si
on
 
ig#p5a'
0.0
0.5
1.0
1.5
2.0
2.5
m
R
N
A 
ex
pr
es
si
on
 
ig#p5b1(
0
10
20
30
40
50
m
R
N
A 
ex
pr
es
si
on
 
ig#p4&
0.00
0.05
0.10
0.15
m
R
N
A 
ex
pr
es
si
on
 
ig#p2a'
0
5
10
15
20
m
R
N
A 
ex
pr
es
si
on
 
ma#x%
0
5
10
15
20
m
R
N
A 
ex
pr
es
si
on
 
murf1&
0
5
10
15
20
m
R
N
A 
ex
pr
es
si
on
 
Igf$2$
0
10
20
30
m
R
N
A 
ex
pr
es
si
on
 
atg4b2'
A	   B	  
C	   D	  
E	   F	  
G	   H	  
I	   J	  
0h	   1h	   3h	   6h	   24h	   48h	   0h	   1h	   3h	   6h	   24h	   48h	  
ig#p6a1	   ig#p6b2	  
ig p5a	   ig#p5b1	  
ig#p4	   ig#p2a	  
ma#x	   f1	  
igf2	   atg4b2	  
  
A	
-DX_24h +DX_24h -DX_48h +DX_48h
0
5
10
15
20
Fi
br
e 
di
am
et
er
 (µ
m
)
***" ###"
-IL1_24h +IL1_24h -IL1_48h +IL1_48h
0
5
10
15
20
25
Fi
br
e 
di
am
et
er
 (µ
m
)
###"
+AA_24h -AA_24h +AA_48h -AA_48h +AA_IGF_24h
0
5
10
15
20
Fi
br
e 
di
am
et
er
 (µ
m
)
***	
###	
+++	
	 	 	 	 +AA+IGF-I 4h	
-IL- ß_24h	 IL- ß_24h	 -IL- ß_48h	 IL-1ß_48h	- EX 	 +DEX 	 -DEX 	 EX_48h	
B	
C	 D	
+DEX	-AA	+IL-1ß	 +AA+	IGF	
150	 150	150	
150	 150	150	
150	 150	150	
150	 150	150	
150	
150	
150	
150	
Control	
Treatment	
a	
e	
i	
m	
b	
f	
j	
n	
c	
g	
k	
o	
d	
h	
l	
p	
-AA	
Treatment	
  
30 
 
 734 
 735 
 736 
Table 1. Results of general linear modelling to investigate differences in gene expression in response to dexamethasone (+DEX) treatment  737 
 738 
Gene P-value 
Treatment 
P-value 
Treatment 
*time-point 
Transcript 
level  
1 hour 
+DEX / 
Control  
1 hour 
Transcript 
level  
3 hour 
+DEX /  
Control  
3 hour 
Transcript 
level  
6 hour 
+DEX / 
Control  
6 hour 
Transcript 
level  
24 hour 
+DEX /  
Control  
24h 
Transcript  
level  
48 hour 
+DEX /  
Control  
48 hour 
igfbp6a1 <0.0001 0.032 0.37(0.17) 0.79 0.24(0.18) 0.47 0.21(0.09) 0.43 0.09(0.07) 0.17 0.08(0.04) 0.11 
igfbp6b2 <0.0001 0.005 0.18(0.08) 1.05 0.24(0.10) 1.66 0.26(0.18) 2.45 0.17(0.07) 3.83 0.31(0.13) 4.58 
mafbx <0.0001 0.054 6.60(3.86) 1.57 8.47(2.25) 1.55 11.16(5.9) 2.78 8.96(2.10) 2.08 7.84(0.66) 0.97 
murf1 0.001 n/a 6.44(1.72) 0.99 7.90(2.58) 1.51 6.36(3.83) 1.28 9.84(3.02) 1.58 11.3(7.31) 2.22 
igfbp5b1 0.002 n/a 0.38(0.26) 1.00 0.97(0.65) 2.85 1.20(0.92) 3.14 0.88(0.68) 5.65 0.90(0.86) 3.56 
igf2 0.002 0.014 9.65(1.52) 0.99 7.91(2.60) 1.01 5.61(1.53) 0.86 5.03(1.28) 1.75 6.39(3.22) 3.09 
igfbp2a 0.003 0.985 0.06(0.01) 1.22 0.05(0.03) 1.83 0.05(0.01) 1.28 0.05(0.05) 1.67 0.05(0.02) 1.48 
atg4b2 0.003 <0.0001 9.35(1.02) 0.94 10.8(2.28) 0.95 12.28(1.64) 1.05 21.9(4.66) 2.06 17.2(2.73) 1.83 
igfbp5a 0.007 0.443 0.46(0.36) 0.86 0.38(0.19) 0.60 0.38(0.35) 0.59 0.15(0.12) 0.21 0.16(0.21) 0.28 
igfbp4 0.046 0.464 23.3(9.00) 0.93 22.8(7.22) 1.11 20.6(7.55) 0.96 14.9(6.13) 1.89 11.5(4.81) 2.03 
atg4b1 0.100 0.082 13.0(2.96) 0.89 15.4(3.24) 0.91 21.4(5.20) 1.08 46.5(10.3) 1.56 43.0(7.94) 1.27 
igfbp3a1 0.311 0.253 1.22(0.37) 0.89 0.95(0.32) 0.71 0.66(0.24) 0.51 0.98(0.53) 0.92 1.43(0.95) 1.24 
igfbp1a1 0.464 0.814 14.2(4.29) 1.31 13.41(4.07) 1.19 12.9(5.56) 1.31 13.9(8.30) 0.85 28.8(16.8) 0.90 
igfbp5b2 0.790 0.203 1.40(1.06) 1.05 2.37(1.90) 1.63 3.30(2.37) 1.80 1.03(0.50) 0.52 0.66(0.39) 0.17 
myl1 0.859 n/a 12.9(13.9) 0.87 15.1(14.0) 1.12 10.7(9.40) 0.71 8.95(10.3) 0.73 9,71(11.1) 1.54 
tnni1 0.969 0.864 0.22(0.18) 0.81 0.28(0.18) 1.03 0.23(0.10) 0.88 0.34(0.29) 1.07 0.48(0.39) 1.81 
 739 
Genes showing a statistically significant response to dexamethasone (+DEX) treatment are underlined. 740 
All values where the +DEX treatment is divided by the control show fold change in transcript levels 741 
n/a: treatment*time-point interaction not assessed (Kruskal-Wallis test applied) 742 
 743 
 744 
  745 
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 747 
Table 2. Results of general linear modelling to investigate differences in gene expression in response to interleukin 1β (+IL-1β) treatment 748 
 749 
Gene P-value 
Treatment 
P-value 
Treatment 
*time-point 
Transcript 
level  
1 hour 
+IL-1β /  
Control  
1 hour 
Transcript 
level  
3 hour 
+IL-1β /  
Control  
3 hour 
Transcript 
level  
6 hour 
+IL-1β / 
Control  
6 hour 
Transcript 
level  
24 hour 
+IL-1β /  
Control  
24h 
Transcript  
level  
48 hour 
+IL-1β /  
Control  
48 hour 
igfbp1a1 0.003 0.556 6.64(1.83) 0.90 5.59(1.45) 0.54 6.24(2.45) 0.69 10.1(3.12) 0.91 18.4(9.41) 0.54 
murf1 0.004 0.124 6.53(1.48) 1.07 7.21(1.78) 1.44 6.84(1.65) 1.63 5.74(3.05) 1.11 5.47(2.26) 1.88 
igfbp3a1 0.128 0.796 0.87(0.34) 0.88 0.67(0.28) 0.51 0.49(0.06) 0.64 0.73(0.42) 1.09 0.55(0.29) 0.72 
igfbp6a1 0.157 0.150 0.14(0.05) 0.83 0.24(0.18) 1.02 1.15(1.22) 2.22 0.79(0.43) 2.66 0.69(0.51) 1.39 
igfbp5b2 0.181 0.955 0.90(0.63) 0.85 1.07(0.61) 0.47 1.50(0.83) 0.65 1.71(0.81) 1.05 1.47(0.87) 0.53 
atg4b1 0.222 n/a 7.75(1.20) 0.89 8.73(0.93) 0.77 13.3(2.89) 0.86 22.3(7.94) 1.17 18.3(7.84) 0.87 
igfbp5b1 0.284 0.675 0.27(0.14) 0.92 0.38(0.34) 1.02 0.46(0.48) 1.33 0.21(0.16) 1.39 0.17(0.14) 2.60 
igfbp4 0.386 0.951 16.1(5.15) 0.92 13.9(4.09) 0.69 12.0(2.48) 0.95 7.41(4.5) 1.36 2.68(1.50) 0.73 
igfbp2a 0.542 0.917 0.06(0.02) 0.88 0.05(0.02) 1.25 0.05(0.01) 0.99 0.05(0.02) 1.31 0.03(0.02) 0.97 
igfbp6b2 0.581 0.695 0.10(0.07) 0.95 0.07(0.06) 0.41 0.07(0.05) 0.80 0.05(0.02) 0.76 0.05(0.02) 1.59 
tnni1 0.646 n/a 0.27(0.18) 1.05 0.26(0.16) 0.91 0.33(0.26) 1.23 0.38(0.28) 1.07 0.28(0.17) 0.93 
igf2 0.680 n/a 5.97(3.74) 1.20 4.48(2.05) 0.72 2.64(1.13) 1.06 1.81(1.13) 1.26 1.30(0.39) 1.01 
atg4b2 0.700 0.213 9.69(1.41) 0.97 10.3(0.71) 0.83 14.3(2.61) 1.05 12.9(5.14) 0.93 12.6(4.28) 1.14 
igfbp5a 0.756 0.977 0.17(0.11) 1.14 0.24(0.18) 0.96 0.21(0.18) 1.31 0.15(0.09) 1.15 0.12(0.07) 0.53 
mafbx 0.791 0.507 3.54(1.04) 1.09 4.02(0.88) 0.62 5.24(2.68) 1.13 4.80(1.88) 1.02 5.22(1.76) 0.79 
myl1 0.938 0.999 10.8(8.10) 1.03 10.8(8.45) 1.09 12.6(15.7) 1.60 8.59(8.30) 0.98 5.07(3.27) 1.17 
 750 
Genes showing a statistically significant response to interleukin 1ß (+IL-1β) treatment are underlined. 751 
All values where the +IL-1β treatment is divided by the control show fold change in transcript levels 752 
n/a: treatment*time-point interaction not assessed (Kruskal-Wallis test applied) 753 
 754 
  755 
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Table 3. Results of general linear modelling to investigate differences in gene expression in response to amino acids deprivation (-AA) treatment 759 
 760 
Gene P-value 
Treatment 
P-value 
Treatment 
*time-point 
Transcript 
level  
1 hour 
-AA /  
Control  
1 hour 
Transcript 
level  
3 hour 
-AA /  
Control  
3 hour 
Transcript 
level  
6 hour 
-AA / 
Control  
6 hour 
Transcript 
level  
24 hour 
-AA /  
Control  
24h 
Transcript  
level  
48 hour 
-AA /  
Control  
48 hour 
igfbp6a1 <0.0001 0.136 0.24(0.07) 0.87 0.13(0.07) 0.40 0.25(0.15) 0.43 0.13(0.07) 0.28 0.12(0.08) 0.20 
mafbx 0.012 0.679 3.74(1.55) 0.82 4.34(0.87) 0.65 3.73(1.22) 0.66 5.02(1.42) 0.92 5.03(1.52) 0.60 
igfbp6b2 0.039 0.747 0.08(0.06) 0.70 0.10(0.10) 0.49 0.06(0.02) 0.47 0.04(0.03) 0.58 0.04(0.03) 0.60 
igfbp5a 0.056 n/a 0.26(0.19) 1.00 0.22(0.19) 0.68 0.28(0.28) 0.74 0.20(0.24) 0.60 0.06(0.08) 0.17 
murf1 0.083 0.734 8.90(3.10) 1.19 9.85(1.64) 1.32 10.3(5.44) 1.26 8,14(3.20) 0.96 11.7(7.73) 2.07 
atg4b2 0.092 0.569 8.06(1.58) 1.08 7.92(1.78) 0.97 7.14(3.26) 0.71 8.21(2.72) 0.74 5.95(1.74) 0.72 
igfbp3a1 0.098 0.154 1.90(1.30) 0.88 1.68(0.52) 0.75 1.89(0.40) 1.14 3.61(1.84) 1.89 5.10(2.75) 2.35 
atg4b1 0.107 0.744 9,56(3.54) 1.09 10.1(2.75) 0.94 10.6(3.18) 0.73 16.3(5.67) 0.68 15.2(6.40) 0.68 
myl1 0.307 0.653 19.1(17.6) 1.38 16.4(16.0) 1.23 12.5(13.4) 0.78 7.00(8.06) 0.45 2.62(1.78) 0.43 
tnni1 0.314 0.911 0.50(0.40) 1.19 0.40(0.25) 0.99 0.35(0.24) 0.72 0.38(0.37) 0.71 0.25(0.15) 0.73 
igfbp2a 0.392 0.919 0.10(0.03) 0.97 0.07(0.02) 0.88 0.07(0.02) 1.12 0.05(0.02) 0.94 0.04(0.01) 0.72 
igf2 0.409 0.504 5.94(5.64) 0.73 4.64(3.30) 0.63 6.33(4.68) 1.58 3.37(2.04) 1.25 5.39(5.36) 2.22 
igfbp1a1 0.627 0.304 18.6(9,98) 0.94 17.84(7.92) 0.98 17.6(5.14) 1.11 25.4(9.43) 1.18 35.9(12.8) 0.63 
igfbp4 0.649 n/a 30.2(20.7) 0.80 29,9(20.3) 0.84 31.8(18.9) 1.20 16.8(9.91) 1.38 12.5(5.74) 1.88 
igfbp5b1 0.843 0.814 0.08(0.04) 0.94 0.100(0.08) 0.98 0.08(0.08) 0.56 0.06(0.05) 1.13 0.03(0.02) 1.06 
igfbp5b2 0.901 0.994 0.50(0.57) 0.88 0.61(0.59) 0.74 1.38(1.14) 1.27 1.09(0.98) 1.24 1.15(1.06) 0.54 
 761 
Genes showing a statistically significant response to amino acids deprivation (-AA) treatment are underlined. 762 
All values where the -AA treatment is divided by the control show fold change in transcript levels 763 
n/a: treatment*time-point interaction not assessed (Kruskal-Wallis test applied) 764 
 765 
 766 
  767 
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Table 4. Results of general linear modelling to investigate differences in gene expression in response to adding amino acids and Igf-I growth factor (+AA 770 
+Igf-I) treatment. 771 
 772 
Gene P-value 
Treatment 
P-value 
Treatment 
*time-
point 
Transcript 
level  
48 hour* 
+AA +Igf-I /  
Control  
48 hour* 
Transcript 
level  
1 hour 
-AA /  
Control  
1 hour 
Transcript 
level  
3 hour 
-AA / 
Control  
3 hour 
Transcript 
level  
24 hour 
-AA /  
Control  
24h 
mafbx <0.0001 0.073 5.03(1.52) 0.60 0.87(0.35) 0.31 0.59(0.26) 0.28 0.98(0.45) 0.55 
atg4b2 0.001 0.186 5.95(1.74) 0.71 31.96(8.12) 0.78 25.03(6.15) 0.57 27.80(11.3) 0.78 
igfbp4 0.002 0.888 12.5(5.74) 1.88 11.36(5.46) 2.09 14.1(7.5) 2.72 7.76(6.04) 2.82 
igf2 0.009 0.824 5.39(5.36) 2.21 10.9(2.68) 1.76 10.9(5.64) 1.85 2.86(1.78) 1.49 
igfbp6b2 0.010 0.171 0.05(0.01) 0.75 1.04(1.23) 3.80 0.29(0.14) 1.35 0.12(0.07) 1.56 
igfbp5b1 0.016 0.354 0.03(0.02) 1.06 0.64(0.66) 2.67 0.66(0.87) 2.12 0.27(0.19) 1.54 
igfbp1a1 0.021 0.760 35.0(12.8) 0.63 7.63(5.65) 0.43 10.1(6.46) 0.68 10.1(5.3) 0.77 
atg4b1 0.033 n/a 15.2(6.24) 0.68 5.03(0.90) 0.59 3.78(0.92) 0.45 6.85(4.51) 0.90 
igfbp5a 0.086 n/a 0.08(0.07) 0.21 0.16(0.05) 1.46 0.26(0.09) 1.65 0.12(0.07) 4.84 
igfbp2a 0.514 0.626 0.04(0.01) 0.72 0.02(0.004) 1.48 0.02(0.01) 1.47 0.02(0.009) 1.43 
murf1 0.608 0.057 11.78(7.73) 2.07 3.59(1.28) 0.81 2.16(1.33) 0.61 3.33(1.33) 0.69 
tnni1 0.689 0.534 0.25(0.15) 0.73 0.27(0.18) 0.77 0.27(0.19) 0.76 0.99(0.71) 1.84 
igfbp5b2 0.834 0.404 1.15(1.06) 0.54 0.20(0.21) 0.96 0.15(0.10) 0.71 0.58(0.48) 1.88 
igfbp3a1 0.875 0.063 5.10(2.75) 2.35 1.03(0.68) 1.44 0.65(0.34) 0.85 0.47(0.25) 0.74 
igfbp6a1 0.877 0.029 0.12(0.08) 0.20 0.12(0.04) 0.84 0.32(0.27) 2.30 0.66(1.09) 4.24 
myl 0.879 n/a 2.62(1.78) 0.43 8.98(12.75) 0.95 12.8(18.4) 1.19 13.5(15.2) 0.98 
 773 
* refers to myotubes being maintained for 48 hours in media free of amino acids for 48 hour before  adding amino acids and Igf-I growth factor (+AA +Igf-I) treatment 774 
Genes showing a statistically significant response to +AA +Igf-I treatment are underlined. 775 
All values where the +AA +Igf-I treatment is divided by the control show fold change in transcript levels 776 
n/a: treatment*time-point interaction not assessed (Kruskal-Wallis test applied). 777 
 778 
 779 
